Myricx Bio, a UK-based biotech firm specializing in novel antibody-drug conjugates (ADCs), has announced the successful closure of a £90m ($114m) Series A financing round. This funding was co-led by Novo Holdings and Abingworth, with participation from new investors such as British Patient Capital, Cancer Research Horizons, and Eli Lilly, along with founding investors Brandon Capital and Sofinnova Partners. The capital will be utilized to enhance Myricx Bio’s proprietary N-Myristoyltransferase inhibitor (NMTi) ADC payload platform and progress its pipeline of NMTi-ADCs through clinical proof of concept. The company intends to establish new laboratory operations in London and expand its R&D and management teams. Joining Myricx Bio’s board are Michael Bauer from Novo Holdings and Lucille Conroy from Abingworth. Myricx has demonstrated significant preclinical success with its ADCs, promising higher efficacy and safety in oncology treatments compared to existing therapies. Key management appointments, including Chris Martin and Francesca Zammarchi, bolster Myricx’s capability to advance its clinical-stage developments.

Biotechnology, Pharmaceuticals,United Kingdom, Global

Myricx Bio Announces £90m ($114m) Series A Financing to Advance its Novel NMTi-ADC Therapeutics into Clinical Development